Author:
Staehli Hodel Eva Maria,Guidi Monia,Zanolari Boris,Mercier Thomas,Duong Socheat,Kabanywanyi Abdunoor M,Ariey Frédéric,Buclin Thierry,Beck Hans-Peter,Decosterd Laurent A,Olliaro Piero,Genton Blaise,Csajka Chantal
Abstract
Abstract
Background
Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability.
Methods
Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM®).
Results
A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs’ pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients.
Conclusion
The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference63 articles.
1. WHO: Guidelines for the treatment of malaria. 2010, Geneva: World Health Organization, Second Edition.
2. WHO: World Malaria Report 2011. 2011, Geneva: World Health Organization
3. Terlouw DJ, Nahlen BL, Courval JM, Kariuki SK, Rosenberg OS, Oloo AJ, Kolczak MS, Hawley WA, Lal AA, Kuile FO: Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. Antimicrob Agents Chemother. 2003, 47: 2929-2932. 10.1128/AAC.47.9.2929-2932.2003.
4. Barnes KI, Watkins WM, White NJ: Antimalarial dosing regimens and drug resistance. Trends Parasitol. 2008, 24: 127-134. 10.1016/j.pt.2007.11.008.
5. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ: Sulfadoxine-pyrimethamine pharmacokinetics in malaria: Pediatric dosing implications. Clin Pharmacol Ther. 2006, 80: 582-596. 10.1016/j.clpt.2006.08.016.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献